GO
Loading...

Bayer AG

More

  • Nov 4- Regeneron Pharmaceuticals Inc cut the top end of its full-year sales forecast for its blockbuster eye drug and reported a lower-than-expected adjusted quarterly profit, citing higher costs. Regeneron's net profit fell to $79.7 million, or 70 cents per share, in the third quarter ended Sept. 30 from $141.3 million, or $1.25 per share, a year earlier.

  • Nov 4- Regeneron Pharmaceuticals Inc reported a higher quarterly revenue on increased sales of its eye injection Eylea. The biotechnology company's net profit fell to $79.7 million, or 70 cents per share, in the third quarter Sept. 30, from $141.3 million, or $1.25 per share, a year earlier. Revenue rose 21.6 percent to $725.8 million and included collaboration...

  • UPDATE 1-FDA panel backs Daiichi's blood thinner Thursday, 30 Oct 2014 | 6:57 PM ET

    Oct 30- A panel of advisers to the U.S. Food and Drug Administration voted 9-1 in favor of approving Japanese drugmaker Daiichi Sankyo Co's blood thinner for use in some patients with atrial fibrillation. According to late-stage trial data submitted by Daiichi, the drug is as effective- and safer than- warfarin, an anticoagulant that has been on the market for more...

  • Oct 28- U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function. The drug, edoxaban, is a once-daily anticoagulant that inhibits Factor Xa, a protein that plays a central role in...

  • Merck beats forecasts, as newer drugs offset generics Tuesday, 29 Jul 2014 | 10:39 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.

  • Big lobbying dollars flow in engineered food fight Tuesday, 29 Jul 2014 | 4:29 AM ET
    A researcher takes tissue samples from genetically modified corn plants.

    The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.

  • Merck proud to be a US-based company: CEO Wednesday, 4 Jun 2014 | 8:52 AM ET
    Ken Frazier, president and CEO of Merck.

    But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.

  • Early movers: WMT, GM, DTV, T & more Thursday, 15 May 2014 | 7:42 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Which M&A deal is best for shareholders? Monday, 12 May 2014 | 12:44 AM ET

    Which M&A deal represents the best value for shareholders?

  • Stocks fell Tuesday after American International Group reported a decline in profit.

  • Merck CEO on future M&A and taxes     Tuesday, 6 May 2014 | 11:16 AM ET

    Merck CEO Kenneth Frazier speaks with CNBC hours after announcing a blockbuster deal with Bayer.

  • Merck CEO done great job: Cramer     Tuesday, 6 May 2014 | 9:11 AM ET

    Merck has agreed to sell its consumer care unit to Bayer for $14.2 million. The "Squawk on the Street" news team discuss the $14.2 billion price tag and product development.

  • U.S. stock index futures pointed to a flat open on Tuesday, ahead of several first-quarter earnings and trade data for March.

  • Early movers: MRK, GE, DTV, AIG, APC, CS & more Tuesday, 6 May 2014 | 7:54 AM ET
    Traders on the floor of the New York Stock Exchange on April 11, 2014

    Some of the names on the move ahead of the open.

  • Aspirin and suntan lotion? Bayer, Merck do deal Tuesday, 6 May 2014 | 7:13 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Bayer will acquire the consumer care business of U.S.-based Merck & Co for $14.2 billion in cash, the company said in a statement Tuesday.

  • I am not a big fan of sanctions: Bayer CEO     Tuesday, 6 May 2014 | 6:10 AM ET

    Marijn Dekkers, Bayer CEO, shares his thoughts on imposing additional sanctions on Russia. I think it's important to sit around the table and come up with diplomatic solutions, says Dekkers.

  • Bayer CEO: Growth huge part of Merck deal     Tuesday, 6 May 2014 | 6:05 AM ET

    Marijn Dekkers, Bayer CEO, discusses the details of his company's acquisition of Merck's consumer unit. Bayer can take these products and position them stronger outside the United States, says Dekkers.

  • FDA questions aspirin's preventative value Monday, 5 May 2014 | 2:33 PM ET

    The FDA said that people should use daily aspirin therapy only after assessing the benefits and risks.

  • Merck profit tops estimate, but revenue misses Tuesday, 29 Apr 2014 | 7:58 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported better-than-expected quarterly earnings, helped by cost cuts and asset sales, but revenue came in slightly below expectations.

  • Early movers: CMCSA, PFE, AZN, GE & more Monday, 28 Apr 2014 | 8:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.